The updated AI-enabled software reportedly facilitates enhanced MRI imaging of the brain, abdomen, and pelvis.
The Food and Drug Administration (FDA) has granted 510(k) clearance for updated artificial intelligence (AI) software that bolsters image quality on magnetic resonance imaging (MRI) scans.
Emphasizing noise reduction without sacrificing diagnostic integrity, the Ezra Flash AI software bolsters the quality of MRI scans of the brain, abdomen and pelvis, according to Ezra, the manufacturer of Ezra Flash AI.
In addition to enhanced neuroimaging, the newly FDA-cleared updates for the Ezra Flash AI software may provide visualization with abdominal and pelvic MRI scans, according to Ezra, the developer of the software. (Images courtesy of Ezra.)
The company maintained that the enhanced image quality obtained with Ezra Flash AI will provide greater clarity in MRI interpretation and precise analysis to facilitate a more timely diagnosis.
"The FDA clearance of Ezra Flash represents a significant advancement in making AI-powered cancer screening more accessible," said Daniel K. Sodickson, M.D., Ph.D, the chief scientific advisor at Ezra and chief of innovation in the Department of Radiology at the New York University Grossman School of Medicine. "This technology enables faster, more accurate early cancer detection, ultimately giving patients and their doctors clearer insights for making informed healthcare decisions."
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.